Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $1.3 million.

  • Taysha Gene Therapies' Other Non-Current Liabilities fell 96.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 96.45%. This contributed to the annual value of $1.3 million for FY2024, which is 16.99% down from last year.
  • As of FY2024, Taysha Gene Therapies' Other Non-Current Liabilities stood at $1.3 million, which was down 16.99% from $1.6 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Other Non-Current Liabilities ranged from a high of $4.1 million in FY2022 and a low of $1.3 million during FY2024.
  • In the last 3 years, Taysha Gene Therapies' Other Non-Current Liabilities had a median value of $1.6 million in 2023 and averaged $2.3 million.
  • Data for Taysha Gene Therapies' Other Non-Current Liabilities shows a maximum YoY tumbled of 61.82% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Other Non-Current Liabilities stood at $4.1 million in 2022, then plummeted by 61.82% to $1.6 million in 2023, then decreased by 16.99% to $1.3 million in 2024.